Elron Ventures : Financial Statements as of June 2023
August 15, 2023 at 05:32 pm IST
Share
ELRON VENTURES LTD.
English Translation of Periodic Report for the Second Quarter of 2023
Filed with the Israel Securities Authority
Part
Content
I
Material Changes and Updates that Occurred in Elron's Business
II
Board of Directors Report
III
Interim Financial Statements
IV
Effectiveness of the Internal Control over Financial Reporting and
Disclosure
ELRON VENTURES LTD.
English Translation of Periodic Report for the Second Quarter of 2023
Filed with the Israel Securities Authority
Part I
Material Changes and Updates that Occurred in Elron's Business for the Three Months ended June 30, 2023
Elron Ventures Ltd.
("Elron" or the "Company")
English Translation of Quarterly Report
for the Second Quarter of 2023
Part I
Material Changes and Updates that Occurred in the Company's
Business in the Three Months Ended June 30, 2023
Details according to Regulation 39A of the Israel Securities Regulations (Periodic
and Immediate Reports), 1970
In this section:
"Board of Directors Report"
English Translation of Elron's Board of
Directors Report for the Second Quarter of
2023, included in Part II of this report.
"Financial Statements"
English Translation of Elron's Interim
Consolidated Financial Statements as of June
30, 2023, included in Part III of this report.
"Annual Report"
Elron's Annual Report for the year ended
December 31, 2022 filed with the Israeli
Securities Authority.
The rest of the terms in this report shall have the meaning ascribed to them in the Annual Report, unless stated explicitly otherwise.
The matters described below are in addition to the developments and changes that occurred in the second quarter of 2023 that were already previously described in Part I of the Company's Quarterly Report for the First Quarter of 2023. The matters described below are presented according to the section numbers in Part I of the Annual Report.
1
1. Section 15 of Part I of the Annual Report - Investments
In the first half of 2023, Elron (directly and indirectly) invested approximately $3.3 million in group companies. For further details, see Section 1.4 of the Board of Directors' Report and Note 3 to the Financial Statements.
2. Section 24 of Part I of the Annual Report - CartiHeal
Sections 24.13 and 24.17- during the second quarter of 2023, CartiHeal began marketing the Agili-C implant in the U.S.A and in other countries, for the first time since the return of CartiHeal shares to the selling shareholders and the cancellation of implementation of the transaction for the sale of CartiHeal to Bioventus. Prior to the cancellation of the transaction and the return of shares, Bioventus commenced marketing the implant.
Yaron Elad
Rony Gur Arie
CEO
VP Finance
August 14, 2023, Tel Aviv, Israel
2
ELRON VENTURES LTD.
English Translation of Periodic Report for the Second Quarter of 2023
Filed with the Israel Securities Authority
Part II
Board of Directors Report for the Second
Quarter of 2023
Attachments
Original Link
Original Document
Permalink
Disclaimer
Elron Electronic Industries Ltd. published this content on 14 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2023 12:01:08 UTC.
Elron Electronic Industries Ltd. is an operational holding company that focuses on building and enhancing technology companies, mainly in the field of medical devices. Its group companies include companies at different stages of development and business maturation, operating in various technology fields, such as medical device and other fields. It is involved in the management of its group companies by means of membership and providing assistance to management. It operates in the Holdings and Corporate Operations segment. It is engaged in matters of policy guidance, strategic planning, marketing, selecting and manning senior management positions, determining the business plan, approving investments and budgets, development and operational guidance, assistance in creating strategic partnerships, and the overall ongoing monitoring of its group companies' performance. Its main group companies include BrainsGate Ltd, Pocared Diagnostics Ltd. and RDC Rafael Development Corporation Ltd.